Advance Auto Parts (NYSE:AAP) remains a favored pick among hedge funds, even as Wall Street analysts offer conflicting price targets and ratings ahead of anticipated 2026 demand growth.
Baird raises its price target on Autoliv (ALV), citing resilience in the automotive safety giant's long-term outlook, even as near-term affordability concerns pressure the broader vehicle market.
Target Corporation promotes Chief Operating Officer Michael Fiddelke to CEO, a move seen by many analysts as doubling down on the existing leadership team despite years of underperformance relative to rivals and the broader market.
Walmart is launching a cross-border shipping initiative early this year, enabling U.S.-based third-party sellers to directly reach consumers in Mexico and Canada, intensifying its e-commerce competition with Amazon.
H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Aptiv PLC sees mixed but upwardly revised price targets from major analysts, with Piper Sandler upgrading the auto tech supplier to Overweight and naming it a top pick for 2026, citing its pragmatic strategy and attractive valuation.
Despite recent guidance revisions, Mobileye Global retains strong buy ratings from analysts who see significant upside potential, as the company positions 2026 for a strategic transition in the autonomous driving sector.
Disney CEO Bob Iger confirmed that AI-generated videos from OpenAI's Sora will begin appearing on Disney+ within months, framing the move as an additive feature for short-form content while downplaying any ripple effects on the company's traditional film and TV pipeline.
While reports surface of potential delays for AMD's next-generation MI450 AI accelerators, major analysts reaffirm bullish price targets, highlighting strong long-term demand and the stock's 100% surge over the past year.
Morgan Stanley has upgraded Johnson & Johnson to 'Overweight,' raising its price target to $262, citing confidence in the healthcare giant's robust pipeline of new pharmaceuticals and medical devices.
Award-winning builder Martin Daly is closing his Scottish business for a new life in Switzerland, joining a growing wave of tradespeople leaving the UK. Industry leaders warn that tax policies, rising costs, and a lack of support for small firms are crippling the sector and jeopardising national housing targets.
As Bob Iger prepares to step down, he highlights a 'healthy competition' between Disney's resurgent parks and its entertainment division to become the company's primary profit driver, with the board close to naming his successor.
Despite a steep share price decline, UiPath is carving out a dominant position in the burgeoning 'agentic AI' market, which promises to automate complex workflows. Strong customer loyalty and improving profitability suggest the automation software provider may be undervalued ahead of a projected industry explosion.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
Nvidia's reported plan for a massive $100 billion investment in OpenAI is encountering significant internal resistance, according to a Wall Street Journal report, casting doubt on one of the most anticipated partnerships in the AI arms race and unsettling markets.
The Pacer Metaurus US Large Cap Dividend Multiplier 400 ETF (QDPL) has shifted from quarterly to monthly distributions, utilizing S&P 500 dividend futures to amplify its yield. This strategic pivot addresses investor demand for regular cash flow, though it introduces variability tied to derivatives markets.
Despite shrinking margins on new vehicle sales, Group 1 Automotive posted its highest-ever annual revenue, powered by robust growth in its service departments and finance operations. The auto retailer credits strategic investments in technician retention and a shift toward higher-margin repair work.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
